Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Reviewγ-D-Glutamylaminomethylphosphonic acid
Description: NMDA antagonist
Biological Activity for γ-D-Glutamylaminomethylphosphonic acid
NMDA antagonist; anticonvulsant.
Technical Data for γ-D-Glutamylaminomethylphosphonic acid
| M. Wt | 240.15 |
| Storage | Store at RT |
| CAS Number | 90632-40-9 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for γ-D-Glutamylaminomethylphosphonic acid
Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service
Please contact Customer Service
References for γ-D-Glutamylaminomethylphosphonic acid
References are publications that support the biological activity of the product.
Davies et al (1982) Differential activation and blockade of excitatory amino acid receptors in the mammalian and amphibian central nervous system. Comp.Biochem.Physiol. 72 211 PMID: 6128141
Jones et al (1984) Suppression of audiogenic seizures in DBA/2 mice by two new dipeptide NMDA receptor antagonists. Neurosci.Lett. 45 157 PMID: 6145126
Jones et al (1984) Structure-activity relations of dipeptide antagonists of excitatory amino acids. Neuroscience 13 573 PMID: 6392929
View Related Products by Target
View Related Products by Product Action
Keywords: g-D-Glutamylaminomethylphosphonic acid, g-D-Glutamylaminomethylphosphonic acid supplier, NMDA, Receptors, 0149, Tocris Bioscience
Citations for γ-D-Glutamylaminomethylphosphonic acid
Citations are publications that use Tocris products.
Currently there are no citations for γ-D-Glutamylaminomethylphosphonic acid.
Reviews for γ-D-Glutamylaminomethylphosphonic acid
There are currently no reviews for this product. Be the first to review γ-D-Glutamylaminomethylphosphonic acid and earn rewards!
Have you used γ-D-Glutamylaminomethylphosphonic acid?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.